Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | Combo: DNA, protein & vector vaccines |
| Study Type: | Phase Ib |
| Species: | Human |
| Stage: | Follow up complete |
| Study Start Date: | 2013-06-18 |
| Study Made Public: | NA |
Title
A Phase Ib randomized double blind placebo controlled clinical trial to evaluate the safety and immunogenicity of the vaccine regimen ALVAC-HIV (vCP1521) followed by AIDSVAX B/E in healthy, HIV-1 uninfected adult participants in South Africa
Description
HVTN 097 is a Phase Ib clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of ALVAC-HIV (vCP1521), AIDSVAX B/E, and bivalent subtype C gp120/MF59.
Sign in to see full information about this study and to download study data.
Products
ALVAC (vCP1521) AIDSVAX B/E Placebo ALVAC Placebo AIDSVAX B/E Saline ENGERIX-B TetavaxIntegrated data
BAMA, ICS, NAb
Non-integrated data
No non-integrated data is available for this study.